ArticleRegenerative engineering and translational medicine2020
Regenerative Cell-Based Therapies: Cutting Edge, Bleeding Edge, and Off the Edge.
Article in Regenerative engineering and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanofiber Technology for Regenerative Engineering.ACS nano · 2020Pooled it
- Exosomes in aging and age-related disorders: mechanisms, therapeutic potentials, and challenges.Journal of translational medicine · 2025Review
- Advanced nanoparticles for osteoarthritis: a review.Frontiers in medicine · 2025Review
- Augmenting osteoporotic bone regeneration through a hydrogel-based rejuvenating microenvironment.Bioactive materials · 2024Article
- The evolution and ongoing challenge of unproven cell-based interventions.Stem cells translational medicine · 2024Review
- Hyaluronic acid-British anti-Lewisite as a safer chelation therapy for the treatment of arthroplasty-related metallosis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Establishing Rationale for the Clinical Development of Cell Therapy Products: Consensus between Risk and Benefit.International journal of stem cells · 2023Review
- The Art of Stem Cell-Based Therapy.Advances in experimental medicine and biology · 2023Article
- Bone marrow-derived mesenchymal stem cell-conditioned medium ameliorates diabetic foot ulcers in rats.Clinics (Sao Paulo, Brazil) · 2023Article
- Stromal Vascular Fraction for Osteoarthritis of the Knee Regenerative Engineering.Regenerative engineering and translational medicine · 2022Article
- Biodegradable Polyphosphazenes for Regenerative Engineering.Journal of materials research · 2022Article
- The synthetic artificial stem cell (SASC): Shifting the paradigm of cell therapy in regenerative engineering.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Platelet-rich plasma-derived extracellular vesicles: A superior alternative in regenerative medicine?Cell proliferation · 2021Review
- Regenerative engineering: a review of recent advances and future directions.Regenerative medicine · 2021Review
- Emergence of the Stem Cell Secretome in Regenerative Engineering.Trends in biotechnology · 2020Review
- Mechanically superior matrices promote osteointegration and regeneration of anterior cruciate ligament tissue in rabbits.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- The paradigm of stem cell secretome in tissue repair and regeneration: Present and future perspectives.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
With the emergence of cell-based therapies as viable treatment options readily accessible to patients, the scientific community and public have raised concerns regarding consumer accessibility and regulation enforcement. Opposing viewpoints regarding regulation have emerged, and efforts to maintain the balance between promoting scientific innovation and ensuring public safety has proved challenging. To further complicate matters, there is contradictory information regarding the clinical safety and efficacy of cell-based treatments. Herein, we outline the FDA's regulatory framework for cell-based therapies and describe what we term the cutting edge, bleeding edge, and off the edge interventions. We conclude with a new classification system for regenerative cell-based therapies intended to further aid in delineating between the clinically and scientifically sound therapies to those that compel further scientific investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.